Seres Therapeutics (MCRB) director Kurt Graves receives 6,500 stock options at $7.14

Rhea-AI Filing Summary

Seres Therapeutics, Inc. director Kurt Graves received a grant of stock options to acquire 6,500 shares of common stock at an exercise price of $7.14 per share. The options expire on July 7, 2036 and vest on the earlier of July 8, 2027 or the day immediately prior to the first annual meeting of stockholders occurring after July 8, 2026.

Insights

Equity Compensation Analyst

Director received a routine stock option grant with long-term vesting.

Director Kurt Graves was granted stock options for 6,500 shares of Seres Therapeutics, Inc. common stock at an exercise price of $7.14 per share. This is classified as a grant or award acquisition, not an open-market purchase or sale.

The options expire on July 7, 2036 and vest on the earlier of July 8, 2027 or the day immediately prior to the first annual meeting after July 8, 2026. This structure ties vesting to continued board service and the company’s stockholder meeting cycle.

No sales or exercises are reported here, and the filing does not indicate any Rule 10b5-1 trading plan. The event represents standard director equity compensation, providing long-term incentive alignment without immediate cash flow impact.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Graves Kurt

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	6,500	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 6,500 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option Shares Granted: 6,500 shares Exercise Price: $7.14 per share Expiration Date: July 7, 2036 +1 more

4 metrics

Option Shares Granted 6,500 shares Stock option grant to director Kurt Graves for common stock

Exercise Price $7.14 per share Conversion or exercise price of the granted stock options

Expiration Date July 7, 2036 Expiration date of the granted stock options

Underlying Shares 6,500 shares Number of common shares underlying the granted stock options

Key Terms

Stock Option, exercise price, vests and becomes exercisable, annual meeting of the Company's stockholders

4 terms

Stock Option financial

"security_title: "Stock Option (right to buy)""

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"conversion_or_exercise_price: "7.1400""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests and becomes exercisable financial

"The option vests and becomes exercisable on the earlier to occur of"

annual meeting of the Company's stockholders regulatory

"the day immediately prior to the first annual meeting of the Company's stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/10/2026 - 04:15 PM Accepted by SEC EDGAR 07/10/2026 - 04:15 PM Learn about SEC filing dates

FAQ

What equity award did director Kurt Graves receive at Seres Therapeutics (MCRB)?

Director Kurt Graves received a grant of stock options for 6,500 shares of Seres Therapeutics common stock. The options have an exercise price of $7.14 per share and an expiration date of July 7, 2036.

Is the Form 4 transaction for MCRB a buy or sell by Kurt Graves?

The Form 4 for MCRB reports an acquisition via a stock option grant to director Kurt Graves. It is classified as a grant/award acquisition, not an open-market purchase or sale of common shares.

When do Kurt Graves’ Seres Therapeutics (MCRB) stock options vest?

The options vest and become exercisable on the earlier of July 8, 2027 or the day immediately prior to the first annual meeting of stockholders occurring after July 8, 2026, tying vesting to future governance milestones.

What is the exercise price and expiration date of the MCRB options granted to Kurt Graves?

The stock options granted to director Kurt Graves have an exercise price of $7.14 per share and an expiration date of July 7, 2036, providing a long-dated incentive window.

How many Seres Therapeutics (MCRB) options does Kurt Graves hold after this grant?

Following this grant, director Kurt Graves holds 6,500 derivative securities in the form of stock options, corresponding to 6,500 underlying shares of Seres Therapeutics common stock as reported in the Form 4.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Graves Kurt

(Last) (First) (Middle)

C/O SERES THERAPEUTICS, INC.

101 CAMBRIDGE PARK DRIVE

(Street)

CAMBRIDGE MASSACHUSETTS 02140

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Seres Therapeutics, Inc. [ MCRB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.14	07/08/2026		A		6,500		(1)	07/07/2036	Common Stock	6,500	$0	6,500	D

Explanation of Responses:

1. The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026.

	/s/ Thomas J. DesRosier, Attorney-in-Fact	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)